Allogene Therapeutics, Inc.·4

Jan 24, 5:02 PM ET

Roberts Zachary 4

4 · Allogene Therapeutics, Inc. · Filed Jan 24, 2023

Insider Transaction Report

Form 4
Period: 2023-01-20
Roberts Zachary
EVP of R&D
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-01-20+873,015873,015 total
    Exercise: $6.55Exp: 2033-01-20Common Stock (873,015 underlying)
  • Award

    Common Stock

    2023-01-20+251,908251,908 total
Footnotes (1)
  • [F1]25% of the shares subject to the stock option shall vest on January 03, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT